In a series of recent announcements, former President Trump has outlined plans to impose a 100% tariff on imports of computer chips and semiconductor products, citing a need for companies to manufacture in the United States. This move is expected to raise costs for consumers on electronic devices. Additionally, Trump has indicated that tariffs on pharmaceutical products may reach as high as 250%, which could also lead to increased drug prices. While some firms like Apple may be exempted from certain tariff implications, the overall impact on the market and domestic businesses remains uncertain. As the financial landscape adjusts, shares in drug companies have already begun to reflect concerns over these potential tariffs.